Feasibility and safety of dose-dense modified docetaxel-cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605490708 | ||
| 003 | CHVBK | ||
| 005 | 20210128100506.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-015-0836-1 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-015-0836-1 | ||
| 245 | 0 | 0 | |a Feasibility and safety of dose-dense modified docetaxel-cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study |h [Elektronische Daten] |c [Séna Yossi, Benjamin Linot, Guillaume Peyraga, Renaud Breheret, Laurent Laccourreye, Olivier Capitain] |
| 520 | 3 | |a Abstract : Background: Docetaxel-cisplatin and 5-fluorouracil (TPF) chemotherapy (days 1-21) represents a standard but toxic regimen for advanced head and neck cancer (HNC). We report a retrospective monocentric study evaluating the safety and the efficacy of a dose-dense modified TPF (mTPF) regimen (days 1-14) in patients with stage III-IV HNC. Methods: Thirty-seven patients retrospectively included from May 2011 to May 2014 were treated with a bimonthly dose-dense mTPF regimen (40mg/m2 docetaxel, 40mg/m2 cisplatin or AUC2 carboplatin, folinic acid 400mg/m2 for 2h, bolus 5-FU 400mg/m2 for 10min and 5-FU 1,000mg/m2/day) by continuous infusion over 46h). Results: Chemotherapy was used as induction or palliative treatment in 12 and 25 patients, respectively, with a median age of 60 years (range 46−83). Median follow-up time was 7.4months (2.53-16.7months). There was no intestinal toxicity in 25 patients (68%). Grade 3-4 hematological toxicity was noticed for 5 (13.5%) patients. Granulocyte-colony stimulating factor was used as primary prophylaxis in 30 patients (81%). After at least 4 delivered cycles, complete responses, partial responses and stable diseases were reported in 5 (15%), 13 (39%) and 5 (15%) of the 33 evaluable patients, respectively, yielding an objective response rate of 54.5% (39% for palliative chemotherapy and 90% for induction chemotherapy). Conclusion: Dose-dense mTPF (days 1-14) is safe and seems to be as effective as TPF (days 1-21). Future prospective trials are required to confirm our results. | |
| 540 | |a Japan Society of Clinical Oncology, 2015 | ||
| 690 | 7 | |a 5-fluorouracil |2 nationallicence | |
| 690 | 7 | |a Docetaxel |2 nationallicence | |
| 690 | 7 | |a Cisplatin |2 nationallicence | |
| 690 | 7 | |a Head and neck cancer |2 nationallicence | |
| 690 | 7 | |a Dose-dense chemotherapy |2 nationallicence | |
| 690 | 7 | |a Quality of life |2 nationallicence | |
| 700 | 1 | |a Yossi |D Séna |u Department of Oncopharmacology-Pharmacogenetics, Integrated Center of Oncology (ICO) Paul Papin, 2 rue Moll, 49033, Angers Cedex 9, France |4 aut | |
| 700 | 1 | |a Linot |D Benjamin |u Department of Oncopharmacology-Pharmacogenetics, Integrated Center of Oncology (ICO) Paul Papin, 2 rue Moll, 49033, Angers Cedex 9, France |4 aut | |
| 700 | 1 | |a Peyraga |D Guillaume |u Department of Oncopharmacology-Pharmacogenetics, Integrated Center of Oncology (ICO) Paul Papin, 2 rue Moll, 49033, Angers Cedex 9, France |4 aut | |
| 700 | 1 | |a Breheret |D Renaud |u Head and Neck Surgery Department, Centre Hospitalier Universitaire, 4 Rue Larrey, 49100, Angers, France |4 aut | |
| 700 | 1 | |a Laccourreye |D Laurent |u Head and Neck Surgery Department, Centre Hospitalier Universitaire, 4 Rue Larrey, 49100, Angers, France |4 aut | |
| 700 | 1 | |a Capitain |D Olivier |u Department of Oncopharmacology-Pharmacogenetics, Integrated Center of Oncology (ICO) Paul Papin, 2 rue Moll, 49033, Angers Cedex 9, France |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/6(2015-12-01), 1086-1092 |x 1341-9625 |q 20:6<1086 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-015-0836-1 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-015-0836-1 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yossi |D Séna |u Department of Oncopharmacology-Pharmacogenetics, Integrated Center of Oncology (ICO) Paul Papin, 2 rue Moll, 49033, Angers Cedex 9, France |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Linot |D Benjamin |u Department of Oncopharmacology-Pharmacogenetics, Integrated Center of Oncology (ICO) Paul Papin, 2 rue Moll, 49033, Angers Cedex 9, France |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Peyraga |D Guillaume |u Department of Oncopharmacology-Pharmacogenetics, Integrated Center of Oncology (ICO) Paul Papin, 2 rue Moll, 49033, Angers Cedex 9, France |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Breheret |D Renaud |u Head and Neck Surgery Department, Centre Hospitalier Universitaire, 4 Rue Larrey, 49100, Angers, France |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Laccourreye |D Laurent |u Head and Neck Surgery Department, Centre Hospitalier Universitaire, 4 Rue Larrey, 49100, Angers, France |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Capitain |D Olivier |u Department of Oncopharmacology-Pharmacogenetics, Integrated Center of Oncology (ICO) Paul Papin, 2 rue Moll, 49033, Angers Cedex 9, France |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/6(2015-12-01), 1086-1092 |x 1341-9625 |q 20:6<1086 |1 2015 |2 20 |o 10147 | ||